| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Redemption of short-term investments | -44,466 | -44,466 |
| Net cash provided by (used in) investing activities | 8,543 | 43,527 |
| Proceeds from exercise of options | 158 | 36 |
| Proceeds from issuance of common shares, net of issuance costs | 23,143 | - |
| Proceeds from issuance of pre-funded warrants, net of issuance costs | -2,573 | - |
| Proceeds from issuance of common stock warrants, net of issuance costs-Seriesa Common Warrants | 9,504 | - |
| Proceeds from issuance of common stock warrants, net of issuance costs-Seriesb Common Warrants | 13,416 | - |
| Proceeds from employee stock purchase plan | 300 | 140 |
| Cash provided by financing activities | 49,094 | 176 |
| Net increase (decrease) in cash and cash equivalents | 21,371 | 17,185 |
| Cash and cash equivalents at beginning of period | 25,314 | - |
| Cash and cash equivalents at end of period | 46,685 | - |
Milestone Pharmaceuticals Inc. (MIST)
Milestone Pharmaceuticals Inc. (MIST)